If Not Now, When? Nonserotype Pneumococcal Protein Vaccines

Area of Science:

• Vaccinology
• Microbiology
• Infectious Diseases

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerated novel vaccine development.
• Streptococcus pneumoniae (pneumococcus) poses a significant global health challenge with over 100 serotypes.
• Current pneumococcal vaccines rely on capsular polysaccharides, increasing complexity and cost with higher valency.

Purpose of the Study:

• To explore alternative vaccine strategies for Streptococcus pneumoniae.
• To investigate the potential of invariant pneumococcal proteins as vaccine targets.
• To leverage modern vaccine technologies for improved pneumococcal vaccines.

Main Methods:

• Review of existing pneumococcal vaccine technology.
• Analysis of invariant protein antigens expressed across pneumococcal serotypes.
• Consideration of recombinant DNA and mRNA technologies for vaccine production.

Main Results:

• Invariant pneumococcal proteins elicit robust immune responses in animal models.
• Recombinant DNA and mRNA technologies offer feasible production methods.
• These proteins are conserved across all >100 pneumococcal serotypes.

Conclusions:

• Invariant pneumococcal proteins represent a promising alternative to capsular polysaccharides for vaccine development.
• Modern technologies like mRNA offer a pathway to affordable and broadly protective pneumococcal vaccines.
• Revisiting vaccine strategies inspired by SARS-CoV-2 could significantly advance pneumococcal immunization.